Medexus Pharmaceuticals (CVE:MDP) Trading Down 4.9%

Medexus Pharmaceuticals Inc. (CVE:MDPGet Free Report)’s share price traded down 4.9% on Wednesday . The company traded as low as C$7.70 and last traded at C$7.75. 40,981 shares were traded during mid-day trading, a decline of 40% from the average session volume of 68,619 shares. The stock had previously closed at C$8.15.

Medexus Pharmaceuticals Price Performance

The stock has a fifty day simple moving average of C$7.75 and a 200-day simple moving average of C$7.75. The company has a current ratio of 1.19, a quick ratio of 0.74 and a debt-to-equity ratio of 1,174.36. The company has a market capitalization of C$148.54 million and a PE ratio of -4.28.

About Medexus Pharmaceuticals

(Get Free Report)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older.

Featured Articles

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with's FREE daily email newsletter.